1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 40 (also presented at TSRC 2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); SKOWRONEK A.(3); HOENG J.(2); PEITSCH M.C.(2); LEE K.M.(1)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Philip Morris Products S.A., R&D, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, U.S.A.
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion by ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 41

    Sharing and reusing data: toxicology assessment meta-analysis of various e-liquids and heat-not-burn platforms with INTERVALS datasets

    STAN A.; BOUÉ S.; HOENG J.; PEITSCH M.C.
    PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Extensive scientific studies are conducted to assess the relative risks of various candidate modified risk tobacco products compared with those of smoking cigarettes. As the scientific community conducts such assessments for diverse products and in a ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STW 02

    Contemporary high-content screening approaches to assess the biological impact of single compounds and complex mixtures in vitro

    FRENTZEL S.(1); THORNE D.(2); MARESCOTTI D.(1); TAYLOR M.(2); BOVARD D.(1); MORELLI M.(1); MATHIS C.(1); HOENG J.(1); GACA M.(2); PEITSCH M.C.(1); PROCTOR C.J.(2)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) British American Tobacco, R&D Centre, Southampton, U.K.
    High-content screening (HCS) is an automated image-based screening technology that allows analysing macroscopically the biological impact of single compounds or complex mixtures on cells growing in multi-well culture dishes. The technology involves ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STW 04

    Multi-organ-on-a-chip platforms to assess the biological impact of toxicants as well as PBPK properties in vitro

    FRENTZEL S.; BOVARD D.; SANDOZ A.; LUETTICH K.; HOENG J.; PEITSCH M.C.
    PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    The merging of three-dimensional (3D) organotypic in vitro models with multi-organ-on-a-chip (MOC) technology has taken in vitro assessment of chemicals to an unprecedented level. By connecting multiple 3D organotypic models, MOCs enable the study of ...
  5. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 30

    Effects of exposure to e-cigarette aerosols compared with cigarette smoke on 3D human buccal and small airway cultures: a systems toxicology assessment

    ISKANDER A.(1); STEINER S.(1); MAJEED S.(1); KONDYLIS A.(1); XIANG Yang(1); ZANETTI F.(1); FRENTZEL S.(1); MARTIN F.(1); PEITSCH M.C.(1); DOSHI U.(2); McKINNEY W.J.(2); LEE K.M.(2); HOENG J.(1)
    (1) Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland; (2) Altria Client Services LLC, Research, Development & Regulatory Affairs, Richmond VA, U.S.A.
    Considerable attention has been given toward the reduced risk potential of e-cigarettes (e-cigs). Most in vitro studies have focused on testing e-liquid formulations directly on submerged 2D cultures. Here, we examined the effects of exposure to the whole ...
  6. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 48

    Six-month systems toxicology inhalation/cessation study in ApoE-/- mice to investigate cardiovascular and respiratory exposure effects of two reduced risk tobacco products compared with conventional cigarettes

    PHILLIPS B.(2); SZOSTAK J.(1); HO J.(2); GUEDJ E.(1); WONG Ee Tsin(2); TALIKKA M.(1); LEBRUN S.(1); TITZ B.(1); MARTIN F.(1); VUILLAUME G.(1); LEROY P.(1); IVANOV N.(1); VANSCHEEUWIJCK P.(1); PEITSCH M.C.(1); HOENG J.(1)
    (1) Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland; (2) Philip Morris International Research Laboratories Pte. Ltd., (part of Philip Morris International group of companies), PMI R&D, Singapore
    Cigarette smoking causes adverse health effects that may occur shortly after smoking initiation and lead to the development of cardiovascular disease, respiratory disease (chronic obstructive pulmonary disease), and various cancers. To reduce the risk of ...
  7. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 61

    A 6-month inhalation study in Apoe-/- mice to investigate cardiovascular and respiratory exposure effects of e-vapor aerosols compared with cigarette smoke

    WONG Ee Tsin(1); SZOSTAK J.(2); KRISHNAN S.(1); TAN Wei Teck(1); SEOW E.(1); TENG C.(1); LEE K.M.(3); ZHANG Jingjie(3); McKINNEY W.J.(3); PEITSCH M.C.(2); VANSCHEEUWIJCK P.(2); HOENG J.(2)
    (1) Philip Morris International Research Laboratories Pte. Ltd., (part of Philip Morris International group of companies), PMI R&D, Singapore; (2) Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland; (3) Altria Client Services LLC, Richmond, VA, U.S.A.
    Chronic exposure to cigarette smoke is a risk factor for the development and progression of cardiovascular disease and chronic obstructive pulmonary disease. Considerable attention has been given towards the potential reduced harm of e cigarettes (e cigs) ...
  8. CORESTA Congress, Berlin, 2016, Agronomy/Phytopathology Groups, AP 22

    Nicotiana genomes: beyond tobacco

    SIERRO N.S.; BATTEY J.N.D.; OUADI S.; THOMAS J.; LIEDSCHULTE V.; BOVET L.; BROYE H.; LAPARRA H.; VUARNOZ A.; LANG G.; GOEPFERT S.; PEITSCH M.C.; IVANOV N.V.
    Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland
    While Nicotiana tabacum is likely the most notable species from the Nicotiana genus, various other Nicotiana species are cultivated as crops, grown as ornamental garden plants, or used as model organisms in research. Within Solanaceae, Nicotiana species ...
  9. CORESTA Meeting, Agronomy/Phytopathology, 2015, Izmir, Turkey, APW 02

    The tobacco genome sequence

    SIERRO N.; BATTEY J.N.D.; OUADI S.; BAKAHER N.; BOVET L.; WILLIG A.; GOEPFERT S.; PEITSCH M.C.; IVANOV N.V.
    Philip Morris Products S.A., PMI R&D, Neuchâtel, Switzerland
    Nicotiana tabacum (common tobacco) is a major crop species and a model organism, for which only very fragmented genomic sequences have been available until recently. The three most commonly used tobacco types are flue-cured (or Virginia), Burley and ...
  10. CORESTA Congress, Sapporo, 2012, Smoke Science/Product Technology Groups, SS 02

    Development of a systems toxicology approach and its application to quantify the biological impact of tobacco smoke in vitro and in vivo

    PEITSCH M.C.; MATHIS C.; WAGNER S.; KOGEL U.; POUSSIN C.; SCHLAGE W.; STINN W.; MEURRENS K.; WEISENSEE D.; GEBEL S.; BELCASTRO V.; XIANG Y.; MARTIN F.; SEWER A.; HENGSTERMANN A.; ANSARI A.; HOENG J.
    Philip Morris International R&D, Philip Morris Products SA, Neuchâtel, Switzerland
    The potential health risks of long-term exposure to biologically active substances such as therapeutic drugs or environmental toxins are frequently determined a posteriori through clinical epidemiology studies. However, disease may take decades to ...